抗雄激素治疗三阴性乳腺癌的现状和进展
1The Second Clinical Medical School of Shandong University, Jinan, 250033, China.
Current medical science
|August 25, 2025
概括
使用AR抗剂的向治疗对雄激素受体 (AR) 阳性三阴性乳腺癌 (TNBC) 是有希望的. 组合治疗和了解AR
科学领域:
- 癌症学
- 分子生物学
- 精准医学
背景情况:
- 三重阴性乳腺癌 (TNBC) 是异质的,需要特定亚型的治疗.
- 具有雄激素受体 (AR) 阳性的TNBC是一种已知的具有治疗潜力的分子亚型.
- 目前对AR阳性TNBC的治疗主要涉及AR抗剂,如埃诺博萨姆,双胺和恩扎胺.
研究的目的:
- 在AR阳性TNBC中探索AR向治疗的治疗潜力.
- 研究组合策略以提高抗AR药物的疗效.
- 阐明AR信号在瘤微环境中的作用及其与免疫疗法的相互作用.
主要方法:
- 在TNBC中对AR向治疗的现有文献的审查.
- 研究AR抗药物的临床前和临床研究分析.
- 探索组合治疗方法,包括化疗,免疫治疗和PARP抑制剂.
主要成果:
- 抗逆转基因药物是抗逆转基因阳性的TNBC的主要药物.
- 结合抗AR药物与化疗,免疫疗法或PARP抑制剂的联合疗法正在研究中.
- AR信号影响瘤微环境,这表明AR抑制可以增强免疫检查点抑制剂的有效性.
结论:
- 针对AR的治疗是个性化治疗AR阳性的TNBC的一个有前途的策略.
- 需要进一步的研究来克服与抗AR疗法相关的局限性和挑战.
- 组合方法有可能改善TNBC的治疗结果.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.2K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.3K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
